290 results on '"Lebrun, Christine"'
Search Results
2. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society
3. Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases
4. Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders
5. Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year
6. Réponses immunitaires au vaccin contre le virus SARS-CoV-2 et infections perthérapeutiques chez des personnes atteintes de sclérose en plaques (SEP) traitées par ocrélizumab (OCR)
7. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial
8. Radiologically isolated syndrome in children: Clinical and radiologic outcomes
9. A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis
10. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
11. Improved EM-Based Tissue Segmentation and Partial Volume Effect Quantification in Multi-sequence Brain MRI
12. A Prospective Study of Patients with Brain MRI Showing Incidental T2 Hyperintensities Addressed as Multiple Sclerosis: a Lot of Work to do Before Treating
13. The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice
14. Vidéo oculographie digitale : étude pilote prospective dans une cohorte de patients atteints de sclérose en plaques
15. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome
16. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies
17. Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls
18. Cancer and multiple sclerosis in the era of disease-modifying treatments
19. Moving to Fingolimod From Natalizumab in Multiple Sclerosis—Reply
20. Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study
21. Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls
22. BEST MS : étude nationale prospective comparant l’efficacité du natalizumab et du fingolimod dans les formes actives de sclérose en plaques
23. Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study
24. Increased risk of multiple sclerosis relapse after in vitro fertilisation
25. Cerebellar volume loss in radiologically isolated syndrome
26. Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-up of 70 Patients
27. Improved EM-Based Tissue Segmentation and Partial Volume Effect Quantification in Multi-sequence Brain MRI
28. Cognitive Functions in Neuromyelitis Optica
29. Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
30. Interferon-β treatment in patients with childhood-onset multiple sclerosis
31. Cortical sclerosis presenting with dementia as a sequel of rapid correction of hyponatraemia
32. Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?
33. Le suivi des sous-populations des lymphocytes B par cytométrie de flux conditionne l’administration du Rituximab (RTX) dans la myasthénie généralisée (MG)
34. Vaccinations et sclérose en plaques : recommandations de la société francophone de la sclérose en plaques
35. De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine
36. Cerebellar volume loss in radiologically isolated syndrome.
37. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis
38. Natalizumab-PML survivors with subsequent MS treatment
39. Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN)
40. Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs
41. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome
42. Anomalies Characteristic of Central Nervous System Demyelination
43. Radiologically isolated syndrome should be treated with disease-modifying therapy – Commentary
44. Hypertension intracrânienne idiopathique dans le cadre d’une obésité ou d’un surpoids : étude observationnelle
45. Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders
46. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
47. De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
48. Effect of repetitive icv injections of ANG II on c-Fos and [AT.sub.1]-receptor expression in the rat brain
49. Une étude multicentrique, ouverte, à un bras, de phase IIIb (CONSONANCE) visant à évaluer l’efficacité et la tolérance d’ocrélizumab chez des patients atteints de SEP-PP et SEP-SP : résultats de l’analyse intermédiaire à 2 ans
50. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.